Think One Test Is All That’s Needed To Detect Cervical Cancer? Think Again

Makeba Giles

Makeba Giles

Content Creator and Curator at MELISASource
Makeba Giles is an Health, Family, and Lifestyle Blogger. She is also a Midwest Mother of four, and the Founder and Creative Director of MELISASource.com. |

EMAIL: [email protected]
Makeba Giles

According to the American Cancer Society, nearly 12,400 women are diagnosed with cervical cancer annually, and more than 4,000 will die of the disease. The incidence of cervical cancer deaths has declined dramatically in the United States due to early detection as a result of screening with the Pap test.

But is the Pap test enough?

There is a debate within the medical community about how to best screen for cervical cancer in women – with a pap test, a hpv – test or both.

In April 2014, the FDA approved an indication for the cobas® HPV test to be used alone as a primary cervical cancer screen in women 25 years of age and older.  The FDA approval was based on a clinical trial that compared HPV testing to Pap testing and involved eight confirmed cervical cancer cases.

However, new results from the largest retrospective analysis of cervical cancer screening strategies in women 30 and older showed that using both pap – and – hpv tests together detects more cervical cancers than either test used alone.

In fact, the quest study found that 1 in 5 women with cervical cancer were missed by screening with hpv alone.

detect cervical cancer

 

Pathologist Dr. R. Marshall Austin is co-author of the study, which is the largest, real‐world retrospective study of cervical cancer screening strategies to date. He joined me recently to share more about the study results, as well as the importance of cervical cancer screening.

detect cervical cancer

Take a look at the interview below.

.

.

For more information on the new study results as well as the pap and hpv tests used to detect cervical cancer, visit: www.papplushpv.com 

detect cervical cancer

.

Meet Our Guest:

R. Marshall Austin, M.D, Ph. D.

Pathologist, MageeWomens Hospital, Pittsburgh, Pennsylvania 

detect cervical cancerDr. R. Marshall Austin is Medical Director of Cytopathology and pathologist in Gynecologic and Breast Surgical Pathology at Magee‐Womens Hospital in Pittsburgh, one of the country’s largest academic hospitals. Austin recently co‐authored the largest, real‐world retrospective study of cervical cancer screening strategies, analyzing approximately 8.6 million women.

Specializing in cytopathology and gynecologic and breast pathology, Dr. Austin’s research focuses on risk management in cervical cancer screenings, gynecological cytopathology and new technology enhancements for cervical cancer screenings. Dr. Austin has published extensive research over the past decade on the performance of cervical screening tests.

In 2014, Dr. Austin was honored by American Society of Cytopathology (ASC) with the Papanicolaou Award‐‐one of the highest honors in his field. Dr. Austin has received the ‘Best Doctors in America’ Award consecutively from 2005‐2015. He also served as past‐President of the ASC in 2004, and he is currently a member of their Golden Papanicolaou Club.

Dr. Austin received both his doctorate of philosophy and medical degree from Duke University inDurham, North Carolina and attended postgraduate training in gynecologic and breast surgical pathology and cytopathology at the Armed Forces Institute of Pathology in Washington D.C.

detect cervical cancer

More from Makeba Giles

6 Techniques to Help Stay Mentally and Emotionally Fit

About Latest Posts Makeba GilesContent Creator and Curator at MELISASourceMakeba Giles is...
Read More

Leave a Reply

Your email address will not be published. Required fields are marked *